Bli medlem
Bli medlem

Du är här

2022-11-18

Klaria Pharma Holding AB: Klaria Interim Report

Klaria Interim report Q3 2022 1 July- 30 September 2022

Summary of the interm report

Third quarter of 2022

- Net sales amounted to 0.0 MSEK (0.0 MSEK)

- Other income amounted to 0.0 MSEK (0.0 MSEK)

- R&D costs for the period amounted to 10.9 MSEK (12.5 MSEK)

- Profit after tax amounted to -16.1 MSEK (-12.2 MSEK)

- Earnings per share for the quarter amounted to -0.27 SEK (-0.24 SEK)

- Cash flow from operating activities amounted to -3.6 MSEK (-13.7 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 6.7 MSEK (25.9 MSEK)

- Equity as of September 30 amounted to 39.3 MSEK (95.2 MSEK)

The Period January-September

- Net sales amounted to 0.0 MSEK (0.0 MSEK)

- Other income amounted to 4.1 MSEK (31.3 MSEK)

- R&D costs for the period amounted to 42.7 MSEK (35.4 MSEK)

- Profit after tax amounted to -50.9 MSEK (-11.4 MSEK)

- Earnings per share for the quarter amounted to -0.88 SEK (-0.22 SEK)

- Cash flow from operating activities amounted to -39.1 MSEK (-10.2 MSEK)

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:

Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com (scott.boyer@klaria.com)
Tel: +46 (0) 8-446 42 99

 

Författare Cision